학술논문
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Document Type
Abstract
Author
Source
In Annals of Oncology December 2023 34(12):1198-1200
Subject
Language
ISSN
0923-7534